Skip to main content
ViroGates A/S logo

ViroGates A/S — Investor Relations & Filings

Ticker · VIRO ISIN · DK0061030574 LEI · 5493007TX8XS56RMZD94 ST Manufacturing
Open in API
Filings indexed 162 across all filing types
Latest filing 2021-09-03 Director's Dealing
Country DK Denmark
Listing ST VIRO

About ViroGates A/S

https://www.virogates.com/

ViroGates A/S is an in-vitro diagnostics company that develops and markets blood tests to measure chronic inflammation. The company's core product line, suPARnostic®, is based on the suPAR (soluble urokinase Plasminogen Activator Receptor) biomarker. This biomarker measures the activation level of the immune system to predict patient outcomes, disease risk, and the severity of chronic inflammation. The primary applications for suPARnostic® products are in hospitals for patient triaging, in the longevity market for health assessment, and in clinical research. The technology aims to improve patient care, optimize resource allocation in healthcare settings, and advance inflammation-based diagnostics.

Recent filings

Filing Released Lang Actions
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19
Director's Dealing Classification · 100% confidence The document is a formal notification of a share transaction by a person discharging managerial responsibilities (PDMR), specifically Thomas Krarup, VP Sales & Marketing at ViroGates. It explicitly references 'MAR art. 19' (Market Abuse Regulation), which governs insider/director dealings. The content details the specific shares sold, prices, volumes, and dates, fitting the definition of a Director's Dealing (DIRS) filing.
2021-09-03 English
ViroGates announces its Half-Year Report for H1 2021: Increasing clinical revenue and positive topline results from COVID-19 clinical trial
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half-Year Report' for ViroGates for the period ending June 30, 2021. It contains comprehensive financial statements (Income Statement, Balance Sheet, Cash Flow Statement), management review, and board statements. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2021
2021-08-19 English
ViroGates announces its Half-Year Report for H1 2021: Increasing clinical revenue and positive topline results from COVID-19 clinical trial
Report Publication Announcement Classification · 95% confidence The document is a company announcement from ViroGates regarding their Half-Year Report for H1 2021. While it contains summary financial data, the text explicitly states: 'This announcement is a summary and should be read in conjunction with ViroGates' Half-Year Report for H1, 2021, published on 19 August 2021. A downloadable PDF version will be available on the company's website.' This confirms the document is an announcement of the report's publication rather than the full report itself, fitting the criteria for a Report Publication Announcement (RPA). H1 2021
2021-08-19 English
ViroGates announces its Half-Year Report for H1 2021: Increasing clinical revenue and positive topline results from COVID-19 clinical trial
Report Publication Announcement Classification · 95% confidence The document is a company announcement from ViroGates regarding their Half-Year Report for H1 2021. While it contains some financial highlights, it explicitly states that it is a summary and refers readers to the full Half-Year Report attached as a PDF. According to the 'Menu vs Meal' rule, since this is an announcement of a report rather than the full report itself, it is classified as a Report Publication Announcement. H1 2021
2021-08-19 English
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19
Director's Dealing Classification · 100% confidence The document is a formal notification of transactions by a person discharging managerial responsibilities (a board member, Jørgen Thorball) at ViroGates A/S. It explicitly references 'MAR art. 19' (Market Abuse Regulation) and provides the standard regulatory disclosure forms for insider dealings, including transaction dates, prices, and volumes. This fits the definition of a Director's Dealing (DIRS) report.
2021-06-11 Danish
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19
Director's Dealing Classification · 100% confidence The document is a formal notification regarding transactions by persons discharging managerial responsibilities (PDMRs) under MAR Article 19. It explicitly details the sale of shares by a director (Jørgen Thorball) and references the attached transaction notification forms. This falls directly under the definition of 'Director's Dealing' (DIRS).
2021-06-11 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.